Merck & Co. Inc. (NYSE:MRK) shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execution across various therapeutic areas.

This strategic move comes as broader markets experienced declines, with major indices like the Dow Jones and S&P 500 both closing lower on the previous trading day.

Restructures Human Health business

Merck has announced a restructuring of its Human Health business, creating an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit.

The Wall Street Journal was the first to report the organizational structuring, noting Merck is shaking up the leadership of its main pharmaceutical unit as the U.S. drug giant gets ready for sales pressure later this decade.

The new structure aims to bolster its leadership in oncology while supporting a growing number of product launches, with the company currently conducting around 80 Phase 3 ...